Developer docs
API playgroundTry for free, no card

Search company profiles

Astaria Global

Full company profile

uuid000ot7e

Namestring
Astaria Global
Legal namestring
Astaria Global
Company typeenum
Private
Founded yearstring
-
Descriptiontext

Astaria Global is a Houston, Texas-based veterinary health company that develops and commercializes Alpha2EQ, an orthobiologic therapy platform for horses. The company's core technology is the patented AlphaActive filtration process — a two-step centrifugation method that functionally isolates alpha-2-macroglobulin (α2M), a naturally occurring anti-inflammatory protein, from the horse's own blood. This autologous preparation is sold as processing kits (Alpha2EQ-30 multi-dose and Alpha2EQ-15 single-dose) to licensed veterinarians, who administer the resulting injectate on-site for lameness, osteoarthritis, joint inflammation, soft tissue injury, and — via a newer nebulizing application using Flexineb equipment — airway inflammation and equine asthma.

The business model is sales-led and exclusively B2B-to-veterinarian: Alpha2EQ is only available through licensed equine veterinarians, with end customers (horse owners, riders, and trainers) accessing the therapy through their vet. Revenue is generated via one-time unit sales of processing kits and bundled Flexineb nebulizer distribution at practitioner pricing, with pay-as-you-go billing per kit and no disclosed subscription or recurring component. Marketing is veterinarian-centric content marketing supported by scientific resources, protocol signup forms, and phone/email support.

The company operated as a privately held Texas LLC with 1–10 employees and was acquired by Creative Science, a CIMA Animal Health company, on April 25, 2025, to expand Creative Science's equine division. The acquisition positions Astaria Global's orthobiologic technology within a larger animal health platform, though the company retains its own brand, product line, and veterinarian-facing distribution identity.

Short descriptiontext

Astaria Global is a Houston-based veterinary health company that sells the patented Alpha2EQ autologous orthobiologic platform — kits that isolate alpha-2-macroglobulin from a horse's own blood to treat lameness, joint inflammation, and airway conditions — exclusively through licensed equine veterinarians.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersHouston, United States
HQ citystring
Houston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
equine orthobiologics, veterinary regenerative medicine, alpha-2-macroglobulin therapy, equine joint therapy, animal health products
Industry2 codes
PRIMARYHLAMAEAC
Equine Therapeutics (Rx)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYHLAMABAJ
Sports Medicine, Lameness & Performance (Equine)
Healthcare & Life Sciences/Veterinary & Animal Health/Large Animal & Equine Veterinary Services
NAICS code1 code
  • Veterinary Services54194
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Equine Orthobiologics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Alpha2EQ Orthobiologic Kit Sales
TypeOne Time License
Description

Sale of proprietary multi-dose blood processing kits (Alpha2EQ-30 and Alpha2EQ-15) to veterinarians for use in autologous equine therapy. The kits are sold directly to veterinarians who then administer the therapy to horse owners. Product can be frozen for future use, extending the value per kit across multiple treatments.

astariaglobal.com
2Nebulizer Equipment Sales
TypeHardware Sales
Description

Distribution of Flexineb nebulizer devices to veterinary practitioners at practitioner pricing, supporting the nebulizing application of Alpha2EQ for equine airway inflammation.

astariaglobal.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Technology or R&D, Marketing or Sales, Personnel, Operations
Pricing details3 tiers
1Alpha2EQ-30 (Multi-dose kit for 2+ injection sites)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Multi-dose kit processes 70mL of blood (2 x 35mL syringes) yielding product for multiple injection sites per visit. Excess can be frozen for future use.

astariaglobal.com
2Alpha2EQ-15 (Single-syringe processing kit)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Smaller volume single-syringe kit for reduced dosing needs.

astariaglobal.com
3Flexineb Nebulizer (Practitioner pricing)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Flexineb nebulizer device available at practitioner pricing for veterinary clinics administering Alpha2EQ nebulizing therapy for equine asthma.

astariaglobal.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Alpha2EQ
Description

Orthobiologic therapy product for equine lameness, joint inflammation, soft tissue injury, and airway inflammation. Powered by the patented AlphaActive filtration process that isolates alpha-2-macroglobulin from horse's own blood.

astariaglobal.com
Core offering1 text field

Astaria Global sells the Alpha2EQ line of autologous orthobiologic therapy kits for horses. Using the patented AlphaActive filtration process, the kits isolate alpha-2-macroglobulin from the horse's own blood on-site at the veterinary clinic. The portfolio includes the Alpha2EQ-30 multi-dose kit (70mL blood volume), the Alpha2EQ-15 single-dose kit (35mL), and a nebulizing formulation for airway inflammation, all targeting equine lameness, osteoarthritis, soft tissue injuries, and equine asthma.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Results of treatment can be observed within a few days of the procedure and may have long-lasting effects of 6–12 months.
+2 more records
Product overview1 text field

Astaria Global offers a unified product portfolio centered on Alpha2EQ, an orthobiologic therapy platform that uses the patented AlphaActive filtration technology to isolate alpha-2-macroglobulin from horses' own blood. The portfolio consists of two processing kit variants—Alpha2EQ-30 (multi-dose, 70mL blood volume) and Alpha2EQ-15 (single-dose, 35mL volume)—for intra-articular injection to address lameness, joint inflammation, and soft tissue injuries, plus a nebulizing formulation for equine airway inflammation and asthma. All products are drug-free, require on-site processing, and leverage the same core AlphaActive filtration mechanism.

Product and service4 records
1Alpha2EQ
CategoryEquine orthobiologic therapy
Description

Autologous orthobiologic therapy that isolates alpha-2-macroglobulin from a horse's own blood using the patented AlphaActive filtration process. Addresses equine lameness, joint inflammation, soft tissue injury, and airway inflammation through a potent biological anti-inflammatory molecule. Sold only to licensed veterinarians for in-clinic administration.

2Alpha2EQ-30
CategoryEquine orthobiologic processing kit
Description

Multi-dose processing kit that processes 70mL of blood (two 35mL syringes) into filtered alpha-2-macroglobulin injectate for multi-site use in a single veterinary visit. Excess product can be frozen for up to 12 months. Sold to licensed veterinarians for treatment of equine lameness, osteoarthritis, synovitis, bursitis, and tendon lesions.

3Alpha2EQ-15
CategoryEquine orthobiologic processing kit
Description

Single-dose processing kit that processes 35mL of blood plus 5mL ACD-A anticoagulant into filtered alpha-2-macroglobulin injectate. Designed for smaller-volume applications and reduced dosing needs in equine joint and soft tissue therapy. Sold to licensed veterinarians.

4Alpha2EQ Nebulizing
CategoryEquine airway inflammation therapy
Description

Alpha2EQ formulation delivered via Flexineb nebulizer for the treatment of equine airway inflammation associated with equine asthma. Includes a nebulizing protocol and pilot study data. Sold to licensed veterinarians, with Astaria Global distributing Flexineb nebulizer devices at practitioner pricing for use in administering this therapy.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-25
Description

Creative Science, a CIMA Animal Health company, acquired Astaria Global on April 25, 2025. The acquisition aims to enhance Creative Science's equine division, reinforce its leadership in equine veterinary care, and broaden its portfolio of animal health companies. Astaria Global's Alpha2EQ orthobiologic technology complements Creative Science's existing equine health solutions.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Terumo BCT sells the Harvest PRP system used by equine veterinarians for autologous platelet-rich plasma therapy in joints and soft tissue. It competes in the same on-site processing, blood-derived biologic category as Alpha2EQ.

TypeBroad incumbent
Description

Zoetis is the largest pure-play animal health company and a broad incumbent in equine pharmaceuticals and biologics. Its portfolio of equine anti-inflammatories, joint therapies, and regenerative offerings (including PulseVet) overlaps with Alpha2EQ's positioning.

TypeDirect peer
Description

Arthrex Vet Systems offers the ACP (Autologous Conditioned Plasma) system for equine joint therapy, the closest direct substitute for Alpha2EQ in the autologous protein injection category. Both companies sell proprietary kits that veterinarians process on-site from the horse's own blood and serve the same equine sports medicine channel.

TypeDirect peer
Description

EmCyte manufactures PRP and autologous biologic kits (PurePRP, Concentrated Bone Marrow Aspirate) used in equine and sports medicine. Like Alpha2EQ, it sells kit-based systems that veterinarians process in-clinic from the patient's own blood.

TypeBroad incumbent
Description

Elanco (now including the Dechra acquisition) is a top-tier animal health company with a substantial equine product portfolio. It competes broadly for the same equine veterinary prescribing and stocking decisions targeted by Alpha2EQ's vet-channel sales motion.

TypeBroad incumbent
Description

Dechra specializes in equine endocrinology, dermatology, and orthopedic pharmaceuticals (including joint therapies). It competes with Alpha2EQ as a broader portfolio incumbent selling equine pain and joint management products to the same veterinarian channel.

TypeDirect peer
Description

PulseVet's focused shockwave therapy devices are widely used in equine sports medicine for the same lameness and soft tissue indications Alpha2EQ addresses. Now part of Zoetis, it is a directly competing modality in the equine regenerative and performance-medicine toolkit.

TypeEmerging player
Description

AniCell Biotech markets amniotic-derived regenerative products for equine joint, soft tissue, and ocular conditions. It is an emerging player focused on a related but different regenerative modality that competes for the same biologic-lameness cases targeted by Alpha2EQ.

9VetStem Biopharma
TypeDirect peer
Description

VetStem provides autologous stem cell therapy for equine joint and soft tissue injuries, competing head-to-head with Alpha2EQ in the regenerative equine lameness market. Both target performance horse owners and equine veterinarians seeking drug-free biologics.

10Boehringer Ingelheim Animal Health
TypeBroad incumbent
Description

Boehringer Ingelheim's equine division markets legend/hyaluronic acid joint therapies and a broad portfolio of equine respiratory and orthopedic drugs that compete in the same equine lameness prescribing decisions as Alpha2EQ.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Astaria Global

Equine Orthobiologicsastariaglobal.com

Astaria Global is a Houston-based veterinary health company that sells the patented Alpha2EQ autologous orthobiologic platform — kits that isolate alpha-2-macroglobulin from a horse's own blood to treat lameness, joint inflammation, and airway conditions — exclusively through licensed equine veterinarians.

What Astaria Global does

Astaria Global is a Houston, Texas-based veterinary health company that develops and commercializes Alpha2EQ, an orthobiologic therapy platform for horses. The company's core technology is the patented AlphaActive filtration process — a two-step centrifugation method that functionally isolates alpha-2-macroglobulin (α2M), a naturally occurring anti-inflammatory protein, from the horse's own blood. This autologous preparation is sold as processing kits (Alpha2EQ-30 multi-dose and Alpha2EQ-15 single-dose) to licensed veterinarians, who administer the resulting injectate on-site for lameness, osteoarthritis, joint inflammation, soft tissue injury, and — via a newer nebulizing application using Flexineb equipment — airway inflammation and equine asthma.

The business model is sales-led and exclusively B2B-to-veterinarian: Alpha2EQ is only available through licensed equine veterinarians, with end customers (horse owners, riders, and trainers) accessing the therapy through their vet. Revenue is generated via one-time unit sales of processing kits and bundled Flexineb nebulizer distribution at practitioner pricing, with pay-as-you-go billing per kit and no disclosed subscription or recurring component. Marketing is veterinarian-centric content marketing supported by scientific resources, protocol signup forms, and phone/email support.

The company operated as a privately held Texas LLC with 1–10 employees and was acquired by Creative Science, a CIMA Animal Health company, on April 25, 2025, to expand Creative Science's equine division. The acquisition positions Astaria Global's orthobiologic technology within a larger animal health platform, though the company retains its own brand, product line, and veterinarian-facing distribution identity.

Astaria Global firmographics

Firmographics
Name
Astaria Global
Legal name
Astaria Global
Website
https://astariaglobal.com
Company type
Private
Operating status
Acquired
Headcount range
1–10 employees
Short description
Astaria Global is a Houston-based veterinary health company that sells the patented Alpha2EQ autologous orthobiologic platform — kits that isolate alpha-2-macroglobulin from a horse's own blood to treat lameness, joint inflammation, and airway conditions — exclusively through licensed equine veterinarians.
Ownership category
akta.pro rank

Astaria Global industry classification

Industry
Product category
Equine Orthobiologics
NAICS
Veterinary Services (54194)
SIC
Biological Products, (No Disgnostic Substances) (2836), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAMAEAC
Equine Therapeutics (Rx)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYHLAMABAJ
Sports Medicine, Lameness & Performance (Equine)
Healthcare & Life Sciences/Veterinary & Animal Health/Large Animal & Equine Veterinary Services

Keywords

  • Equine orthobiologics
  • Veterinary regenerative medicine
  • Alpha-2-macroglobulin therapy
  • Equine joint therapy
  • Animal health products

Where Astaria Global is headquartered

Location

Headquarters

HQ city
Houston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Astaria Global business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Marketing or Sales, Personnel, Operations

Revenue model

  1. Alpha2EQ Orthobiologic Kit Sales: Sale of proprietary multi-dose blood processing kits (Alpha2EQ-30 and Alpha2EQ-15) to veterinarians for use in autologous equine therapy. The kits are sold directly to veterinarians who then administer the therapy to horse owners. Product can be frozen for future use, extending the value per kit across multiple treatments.
  2. Nebulizer Equipment Sales: Distribution of Flexineb nebulizer devices to veterinary practitioners at practitioner pricing, supporting the nebulizing application of Alpha2EQ for equine airway inflammation.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goAlpha2EQ-30 (Multi-dose kit for 2+ injection sites)
Unit PricingPay-as-you-goAlpha2EQ-15 (Single-syringe processing kit)
Unit PricingPay-as-you-goFlexineb Nebulizer (Practitioner pricing)

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Astaria Global product offering

Product offering

Core offering

Astaria Global sells the Alpha2EQ line of autologous orthobiologic therapy kits for horses. Using the patented AlphaActive filtration process, the kits isolate alpha-2-macroglobulin from the horse's own blood on-site at the veterinary clinic. The portfolio includes the Alpha2EQ-30 multi-dose kit (70mL blood volume), the Alpha2EQ-15 single-dose kit (35mL), and a nebulizing formulation for airway inflammation, all targeting equine lameness, osteoarthritis, soft tissue injuries, and equine asthma.

Product overview

Astaria Global offers a unified product portfolio centered on Alpha2EQ, an orthobiologic therapy platform that uses the patented AlphaActive filtration technology to isolate alpha-2-macroglobulin from horses' own blood. The portfolio consists of two processing kit variants—Alpha2EQ-30 (multi-dose, 70mL blood volume) and Alpha2EQ-15 (single-dose, 35mL volume)—for intra-articular injection to address lameness, joint inflammation, and soft tissue injuries, plus a nebulizing formulation for equine airway inflammation and asthma. All products are drug-free, require on-site processing, and leverage the same core AlphaActive filtration mechanism.

Differentiator

Problem solved

Functional benefit

Brands

  • Alpha2EQ: Orthobiologic therapy product for equine lameness, joint inflammation, soft tissue injury, and airway inflammation. Powered by the patented AlphaActive filtration process that isolates alpha-2-macroglobulin from horse's own blood.

Products and services

  • Alpha2EQ Autologous orthobiologic therapy that isolates alpha-2-macroglobulin from a horse's own blood using the patented AlphaActive filtration process. Addresses equine lameness, joint inflammation, soft tissue injury, and airway inflammation through a potent biological anti-inflammatory molecule. Sold only to licensed veterinarians for in-clinic administration.
  • Alpha2EQ-30 Multi-dose processing kit that processes 70mL of blood (two 35mL syringes) into filtered alpha-2-macroglobulin injectate for multi-site use in a single veterinary visit. Excess product can be frozen for up to 12 months. Sold to licensed veterinarians for treatment of equine lameness, osteoarthritis, synovitis, bursitis, and tendon lesions.
  • Alpha2EQ-15 Single-dose processing kit that processes 35mL of blood plus 5mL ACD-A anticoagulant into filtered alpha-2-macroglobulin injectate. Designed for smaller-volume applications and reduced dosing needs in equine joint and soft tissue therapy. Sold to licensed veterinarians.
  • Alpha2EQ Nebulizing Alpha2EQ formulation delivered via Flexineb nebulizer for the treatment of equine airway inflammation associated with equine asthma. Includes a nebulizing protocol and pilot study data. Sold to licensed veterinarians, with Astaria Global distributing Flexineb nebulizer devices at practitioner pricing for use in administering this therapy.

Quantifiable outcome

  • Results of treatment can be observed within a few days of the procedure and may have long-lasting effects of 6–12 months.
  • +2 more outcomes

Companies that use Astaria Global

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Astaria Global technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Astaria Global partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Creative Science (CIMA Animal Health)coreStrategic or Co-development Partner · 25 April 2025Creative Science, a CIMA Animal Health company, acquired Astaria Global on April 25, 2025. The acquisition aims to enhance Creative Science's equine division, reinforce its leadership in equine veterinary care, and broaden its portfolio of animal health companies. Astaria Global's Alpha2EQ orthobiologic technology complements Creative Science's existing equine health solutions.

Scale indicators1 record

Recent moves6 records

Expansion highlights4 records

Astaria Global competitors and assessment

Company assessment

Direct peers

  • Terumo BCT (Harvest): Terumo BCT sells the Harvest PRP system used by equine veterinarians for autologous platelet-rich plasma therapy in joints and soft tissue. It competes in the same on-site processing, blood-derived biologic category as Alpha2EQ.
  • Arthrex Vet Systems: Arthrex Vet Systems offers the ACP (Autologous Conditioned Plasma) system for equine joint therapy, the closest direct substitute for Alpha2EQ in the autologous protein injection category. Both companies sell proprietary kits that veterinarians process on-site from the horse's own blood and serve the same equine sports medicine channel.
  • EmCyte Corporation: EmCyte manufactures PRP and autologous biologic kits (PurePRP, Concentrated Bone Marrow Aspirate) used in equine and sports medicine. Like Alpha2EQ, it sells kit-based systems that veterinarians process in-clinic from the patient's own blood.
  • PulseVet (Zoetis): PulseVet's focused shockwave therapy devices are widely used in equine sports medicine for the same lameness and soft tissue indications Alpha2EQ addresses. Now part of Zoetis, it is a directly competing modality in the equine regenerative and performance-medicine toolkit.
  • VetStem Biopharma: VetStem provides autologous stem cell therapy for equine joint and soft tissue injuries, competing head-to-head with Alpha2EQ in the regenerative equine lameness market. Both target performance horse owners and equine veterinarians seeking drug-free biologics.

Broad incumbents

  • Zoetis: Zoetis is the largest pure-play animal health company and a broad incumbent in equine pharmaceuticals and biologics. Its portfolio of equine anti-inflammatories, joint therapies, and regenerative offerings (including PulseVet) overlaps with Alpha2EQ's positioning.
  • Elanco Animal Health: Elanco (now including the Dechra acquisition) is a top-tier animal health company with a substantial equine product portfolio. It competes broadly for the same equine veterinary prescribing and stocking decisions targeted by Alpha2EQ's vet-channel sales motion.
  • Dechra Pharmaceuticals: Dechra specializes in equine endocrinology, dermatology, and orthopedic pharmaceuticals (including joint therapies). It competes with Alpha2EQ as a broader portfolio incumbent selling equine pain and joint management products to the same veterinarian channel.
  • Boehringer Ingelheim Animal Health: Boehringer Ingelheim's equine division markets legend/hyaluronic acid joint therapies and a broad portfolio of equine respiratory and orthopedic drugs that compete in the same equine lameness prescribing decisions as Alpha2EQ.

Emerging players

  • AniCell Biotech: AniCell Biotech markets amniotic-derived regenerative products for equine joint, soft tissue, and ocular conditions. It is an emerging player focused on a related but different regenerative modality that competes for the same biologic-lameness cases targeted by Alpha2EQ.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

Astaria Global social profiles

Digital presence

Astaria Global financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Astaria Global leadership team

Management profile

Number of profiles

Profiles1 record

Astaria Global funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Astaria Global M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Astaria Global

What does Astaria Global do?

Astaria Global sells the Alpha2EQ line of autologous orthobiologic therapy kits for horses. Using the patented AlphaActive filtration process, the kits isolate alpha-2-macroglobulin from the horse's own blood on-site at the veterinary clinic. The portfolio includes the Alpha2EQ-30 multi-dose kit (70mL blood volume), the Alpha2EQ-15 single-dose kit (35mL), and a nebulizing formulation for airway inflammation, all targeting equine lameness, osteoarthritis, soft tissue injuries, and equine asthma.

Is Astaria Global a public or private company?

Astaria Global is a private company. It is classified as corporate owned and is currently acquired.

When was Astaria Global founded?

Astaria Global was founded in -1. It employs 1 to 10 people.

Where is Astaria Global based?

Astaria Global is headquartered in Houston, United States, in the North America region.

How does Astaria Global make money?

Two revenue lines are on record. Alpha2EQ Orthobiologic Kit Sales are the primary driver. The others are nebulizer Equipment Sales.

Who are Astaria Global's main competitors?

Direct peers on record are Terumo BCT (Harvest), Arthrex Vet Systems, EmCyte Corporation, PulseVet (Zoetis) and VetStem Biopharma. Broad incumbents are Zoetis, Elanco Animal Health, Dechra Pharmaceuticals and Boehringer Ingelheim Animal Health. AniCell Biotech is listed as an emerging player.

Does Astaria Global have an API?

No public API is recorded for Astaria Global.

What industry is Astaria Global in?

Astaria Global's product category is Equine Orthobiologics. Its primary akta.pro industry code is HLAMAEAC, Equine Therapeutics (Rx), with a secondary code of HLAMABAJ, Sports Medicine, Lameness & Performance (Equine). Its NAICS code is 54194 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals